Boston, USA and Tel Aviv Israel-based, the leading provider of medication management technology and pioneer of Pharmaco-Clinical Intelligence, FeelBetter raised USD 5.9 million in funding. The company announced the investment on August 2, 2023. Firstime Ventures and Shoni Health Ventures led the financing for the firm. Meanwhile, Random Forest VC, The Group Ventures, and existing FeelBetter investor Triventures joined in the funding.
So far, the total funds raised by the company now amount to USD 8 million.
What the company’s official has to add
Liat Primor, FeelBetter’s CEO and Co-Founder, said, “FeelBetter’s purpose-built technology makes it possible to deliver a more personalized, whole-patient approach to medication management – one that goes beyond a single illness, diagnosis, or point in time, and comprehensively focuses on each individual’s care journey. At a time when investors are especially selective about the types of bets they are taking, this round and vote of confidence from the world-class teams at Fristime Ventures, Shoni Health Ventures, Random Forest VC, Triventures, and The Venture Group, as well as angel investors, validates the need for and potential of our Pharmaco-Clinical Intelligence as a solution for the growing, global health challenge posed by suboptimal medication management.”
In addition, Yoram Hordan, FeelBetter’s CTO, COO, and Co-Founder, said, “The funding will enable us to expand our reach, further refine our solution, and empower more healthcare providers to deliver personalized, proactive care. Our Pharmaco-Clinical Intelligence, developed collaboratively by clinical and pharmacology experts alongside technology and machine learning specialists, seamlessly matches a patient’s specific clinical and pharmacology data with their sequence of health events. This unlocks unparalleled accuracy in detecting at-risk patients both individually and population-wide and enables new levels of precision in disease management and prevention.”
What the investors have to add
Michael Kerbis, Founding Partner Random Forest VC, further said, “FeelBetter’s algorithm has been trained on two decades of longitudinal clinical, pharmacy, claims, and lab data from hundreds of thousands of patients to find patterns in the complex connections and relationships between disparate data sources. When taken together, these patterns can capture the full picture of a patient’s health journey, enabling FeelBetter to predict which individuals are at the greatest risk of adverse events related to suboptimal medication regimens and recommend timely clinical interventions to drive better health outcomes.”
Besides, Eran Lerer, CEO and Managing Partner, Shoni Health Ventures, said, “From risk stratifying patients to preventing adverse events so patients can safely stay in their communities, FeelBetter offers a proven, end-to-end solution for the suboptimal medication management problem. It’s a groundbreaking tool that is poised to change how the medical community approaches polypharmacy, and we’re thrilled to take part in this important transformation.”
In addition, Keren Kopilov, Partner, Firstime Ventures, said, “By incorporating the expertise of physicians and clinical pharmacists, as well as leveraging data from all relevant sources, FeelBetter provides a solution that is uniquely comprehensive. It intuitively fits into clinical workflows and enables optimized medication management at unparalleled speed and scale. We look forward to leveraging our expertise to support FeelBetter’s mission and continued growth as it meets the tremendous opportunities ahead.”
About the company
Liat Primor and Yoram Hordan launched the company in 2018. FeelBetter is the pioneer of Pharmaco-Clinical Intelligence. It revolutionizes the polypharmacy paradigm on both an individual and population health level with a comprehensive solution designed to tackle the challenges associated with suboptimal medication management.
The company leverages AI and machine learning capabilities to drive personalized medication management, and aid healthcare professionals in ensuring that their patients’ medication regimens are safe, effective, and appropriate.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
